Clinical Trials Logo

Mucopolysaccharidosis Type 7 clinical trials

View clinical trials related to Mucopolysaccharidosis Type 7.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01856218 Completed - Clinical trials for Mucopolysaccharidosis Type 7

An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

UX003-CL201 is an open-label Phase 1/2 study to assess the safety, efficacy, and dose of UX003 in MPS 7 patients via intravenous (IV) administration every other week (QOW) for 36 weeks with up to an additional 36 weeks from the optional continuation period. Up to 5 participants, who are between 5 and 30 years of age inclusive, will be enrolled and treated with UX003. The initial 12-week treatment period will be followed by a 24-week forced dose titration period to assess the optimal dose. Participants who complete both the initial treatment and forced dose titration periods will continue treatment in a 36- week continuation period.